Mammotome Accelerates Production as Public Health Response to Nationwide Breast Biopsy Needle Shortage
Cincinnati-based breast care company expands capacity and provider support to help minimize diagnostic delays and restore patient access to critical procedures CINCINNATI, Sept. 3, 2026 /PRNewswire/ -- Mammotome, a Danaher Company and global leader in breast care innovation, has expanded...
Covered in this story
What has happened since
- Danaher Corporation is up 6.3% since this was published, 47 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Danaher Corporation
- UBS: $205 → $250 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DHR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Danaher Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.